Additionally, combination therapy targeting MET with checkpoint inhibition or TP53 with checkpoint inhibition should be considered in treating EGFR WT, TP53 and/or MET amplified NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.